Pfizer (PFE) is back in focus after its second quarter results came in ahead of internal expectations, prompting the company to lift full year revenue guidance and spotlight progress in key non COVID therapies.

Pfizer's recent earnings beat, higher full year revenue guidance and progress in drugs like Eliquis and LITFULO have coincided with a 7.5% 30 day share price return and an 11.9% 1 year total shareholder return, although longer term total shareholder returns remain weak.

If you want to see how other healthcare names are responding to similar trends in new treatments and pipelines, it could be worth scanning 43 healthcare AI stocks

After a 7.5% 30 day jump, Pfizer still trades below both analyst targets and some intrinsic value estimates. Is that discount a sign the market is too cautious, or a fair reflection of patent risks and recent impairments?

Most Popular Narrative: 9.9% Undervalued

The most followed narrative on Pfizer pegs fair value at about $29.19 a share, slightly above the last close at $26.31, and builds that gap around pipeline execution and long term margin assumptions.

Robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, with multiple high-potential launches and label expansions (e.g., Elrexfio in multiple myeloma, SV in non-small cell lung cancer, advanced ADC portfolio, and pipeline vaccines), stands to drive sustained long-term revenue and earnings growth by addressing rising global demand for innovative therapies as the population ages.

Want to see what sits behind that pipeline story and fair value gap? The narrative focuses on future earnings power, margin rebuild, and a richer earnings multiple tied to those targets.

Result: Fair Value of $29.19 (UNDERVALUED)

However, Pfizer's story can change quickly if patent expiries on key drugs bite harder than expected, or if tighter drug pricing rules compress margins faster than analysts model.

Another Look At Pfizer’s Valuation Using P/E

The SWS DCF model flags Pfizer as trading about 64% below an assessed fair value of $73.57 per share, which suggests a wide upside gap. The P/E picture is very different. At 34.6x earnings versus a fair ratio of 24.4x and a US Pharmaceuticals average of 17.2x, the stock screens expensive. Which lens do you treat as more reliable for your own work?

To see how this earnings based view compares with detailed ratio work, check the valuation breakdown next through See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the split sentiment around Pfizer has you on the fence, review the details promptly and decide where you stand based on 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond Pfizer?

If Pfizer has sharpened your focus on quality, do not stop here. Use powerful screeners to uncover other stocks that might fit your approach.

• Spot potential mispricings early and scan companies that look cheap against their fundamentals with the 49 high quality undervalued stocks.
• Strengthen your income plan by filtering for companies offering higher yields using the 9 dividend fortresses.
• Limit unpleasant surprises by concentrating on companies assessed with lower risk profiles through the 85 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.